Biovica International AB Class B (SE:BIOVIC.B)
:BIOVIC.B
Want to see SE:BIOVIC.B full AI Analyst Report?
Top Page
Biovica International AB Class B
(BIOVIC.B)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.37
▲(4.57% Upside)
Action:ReiteratedDate:03/20/26
The score is driven primarily by weak financial performance—ongoing losses and significant cash burn outweigh improving revenue growth and a low-leverage balance sheet. Technicals add pressure with price below major moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend yield support.
Positive Factors
Proprietary diagnostic platform
Biovica’s DiviTum platform is a proprietary biomarker test focused on tumor proliferation monitoring in oncology. A differentiated, clinic-ready platform supports durable commercial channels (labs, hospitals, pharma trials) and creates structural barriers to entry versus generic diagnostics.
Negative Factors
Persistent cash burn
Sustained large negative operating and free cash flows mean Biovica cannot self-fund growth and must access external capital or cut costs. This structural cash burn increases financing risk and can constrain commercial expansion or clinical study support over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary diagnostic platform
Biovica’s DiviTum platform is a proprietary biomarker test focused on tumor proliferation monitoring in oncology. A differentiated, clinic-ready platform supports durable commercial channels (labs, hospitals, pharma trials) and creates structural barriers to entry versus generic diagnostics.
Read all positive factors
Biovica International AB Class B (BIOVIC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr101.08M
Dividend YieldN/A
Average Volume (3M)324.11K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue Growth33.12%
EPS Growth64.71%
CountrySE
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding277,487,200
10 Day Avg. Volume299,971
30 Day Avg. Volume324,106
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.50
Price to Sales (P/S)7.52
P/FCF Ratio-0.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr39.90M
Biovica International AB Class B Business Overview & Revenue Model
Company Description
Biovica International AB Class B (BIOVIC.B) is a biotechnology company based in Sweden, specializing in the development of diagnostic solutions for cancer. The company focuses on improving the management of cancer treatment through its innovative ...
How the Company Makes Money
Biovica makes money primarily by selling and supporting its proprietary diagnostic tests and related services based on the DiviTum platform. Revenue is generated from (1) commercial sales of DiviTum-based assays used for monitoring therapy respons...
Biovica International AB Class B Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.90M | 8.62M | 7.29M | 3.38M | 2.04M | 2.08M |
| Gross Profit | -27.99M | 8.08M | 6.88M | 4.62M | 4.67M | 5.27M |
| EBITDA | -63.19M | -76.22M | -119.51M | -105.96M | -53.47M | -36.56M |
| Net Income | -71.50M | -87.62M | -124.82M | -110.49M | -60.00M | -39.48M |
Balance Sheet | ||||||
| Total Assets | 126.51M | 64.95M | 131.41M | 172.29M | 151.63M | 192.65M |
| Cash, Cash Equivalents and Short-Term Investments | 88.22M | 24.41M | 79.41M | 114.33M | 89.79M | 145.36M |
| Total Debt | 4.84M | 4.65M | 7.83M | 10.45M | 13.25M | 2.42M |
| Total Liabilities | 20.56M | 21.74M | 34.77M | 33.65M | 27.54M | 9.99M |
| Stockholders Equity | 105.95M | 43.21M | 96.64M | 138.63M | 124.09M | 182.66M |
Cash Flow | ||||||
| Free Cash Flow | -64.91M | -85.65M | -114.72M | -97.42M | -55.52M | -37.97M |
| Operating Cash Flow | -64.65M | -85.37M | -114.58M | -94.64M | -52.13M | -34.41M |
| Investing Cash Flow | -263.00K | -287.00K | -585.00K | -2.78M | -3.40M | -3.56M |
| Financing Cash Flow | 110.14M | 30.93M | 79.50M | 122.01M | -136.00K | 142.66M |
Biovica International AB Class B Technical Analysis
Negative
0.35
Price Trends
0.36
Negative
0.41
Negative
0.52
Negative
Market Momentum
>-0.01
Positive
45.64
Neutral
36.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.36, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.64 is Neutral, neither overbought nor oversold. The STOCH value of 36.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOVIC.B.
Biovica International AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr101.08M | -1.81 | -72.82% | ― | 33.12% | 64.71% | |
45 Neutral | kr65.45M | -1.34 | -294.38% | ― | 45.38% | 57.56% | |
44 Neutral | kr122.76M | -1.48 | -52.45% | ― | -5.23% | 47.93% | |
43 Neutral | kr68.57M | -3.17 | -21.31% | ― | 230.00% | 16.14% | |
43 Neutral | kr1.51M | -0.11 | -213.85% | ― | -100.00% | 35.95% | |
42 Neutral | kr23.13M | -1.86 | -120.13% | ― | ― | 24.27% |
* Healthcare Sector Average
SE:BIOVIC.B
Biovica International AB Class B
0.35
-0.39
-52.57%
SE:ALZ
Alzinova AB
0.44
-1.57
-78.06%
SE:BIOSGN
Biosergen AB
9.85
-22.45
-69.50%
SE:NICA
Nanologica AB
0.53
-0.67
-55.46%
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.09
-89.32%
SE:NXTCL
NextCell Pharma AB
1.10
-0.03
-2.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.